Bart Barlogie

High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

137 h-index 1155 pubs 75,768 cited

Research Areas

Links

ORCID Lab Website Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Bart Barlogie's research focuses on the molecular and spatial evolution of multiple myeloma, investigating the pathways from precursor conditions to advanced disease states. His work includes analyzing the molecular makeup of smoldering myeloma and its spatio-temporal evolution from baseline to relapse-refractory stages. He has published research on resolving the spatial architecture of myeloma and its microenvironment at the single-cell level, as well as identifying gene signatures that can predict the risk of monoclonal gammopathy of undetermined significance (MGUS) progressing to multiple myeloma.

Further research by Barlogie examines factors influencing disease progression and treatment outcomes. This includes investigating high-risk transcriptional profiles in multiple myeloma, which are identified as acquired features that can occur with each subsequent relapse. He has also explored the feasibility of outpatient stem cell transplantation for multiple myeloma patients and identified risk factors predictive of hospital admission. His work extends to understanding the mechanisms by which specific molecules, such as CST6, suppress osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. Barlogie has also contributed to the development and validation of individualized prognostic score systems for patients with newly diagnosed multiple myeloma.

Barlogie's extensive publication record is reflected in his h-index of 137 and over 75,000 citations across more than 1,155 publications. He leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Sharmilan Thanendrarajan, John D. Shaughnessy Jr., and Carolina Schinke, with whom he has co-authored multiple publications.

Metrics

h-index: 137
Publications: 1155
Citations: 75,768

Selected Publications

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024) DOI
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211 (2023) DOI
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023) DOI
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level (2023) DOI
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023) DOI
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023) DOI
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022) DOI
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022) DOI
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022) DOI
N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma (2021) DOI
High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse (2021) DOI